Renal denervation as a management strategy for hypertension: current evidence and recommendations

References

• Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165–182.
   PubMed Web of Science ®Google Scholar
• GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-1249.
   Google Scholar
• Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749–1757.
   PubMed Web of Science ®Google Scholar
• Wojciechowski D, Papademetriou V, Faselis C, et al. Evaluation and treatment of resistant or difficult-to-control hypertension. J Clin Hypertens (Greenwich). 2008;10(11):837–843.
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–1642.
   PubMed Web of Science ®Google Scholar
• Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076–1080.
   PubMed Web of Science ®Google Scholar
• de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902.
   PubMed Web of Science ®Google Scholar
• Ludwig C. De viribus physicis secretionem urinae adjuvantibus: marburge Cattorum. Elwert, Marburg; 1842.
   Google Scholar
• Bradford JR. The Innervation of the Renal Blood Vessels. J Physiol. 1889;10(5):358–43218.
   PubMedGoogle Scholar
• Sen S. Some observations on decapsulation and denervation of the kidney. Br J Urol. 1936;8(4):319–328.
   Google Scholar
• Papin E, Ambard L. Resection of the nerves of the kidney for nephralgia and small hydronephroses. J Urol. 1924;11(4):337.
   Google Scholar
• Page DL. Lipomatous hypertrophy of the cardiac interatrial septum: its development and probable clinical significance. Hum Pathol. 1970;1(1):151–163.
   PubMedGoogle Scholar
• Page IH, Heuer GJ. The Effect of Renal Denervation on Patients Suffering from Nephritis. J Clin Invest. 1935;14(4):443–458.
   PubMedGoogle Scholar
• Smithwick RH, Thompson JE. Splanchnicectomy for Essential Hypertension - Results in 1,266 Cases. Journal of the American Medical Association. 1953;152(16):1501–1504.
   PubMed Web of Science ®Google Scholar
• Grimson KS, Orgain ES, Anderson B, et al. Total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy for hypertension. Ann Surg. 1953;138(4):532–547.
   PubMed Web of Science ®Google Scholar
• The EM. Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol. 2009 1985). 2010;108(2):227–237.
   PubMed Web of Science ®Google Scholar
• Bohm M, Linz D, Ukena C, et al. Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond? Circ Res. 2014;115(3):400–409.
   PubMed Web of Science ®Google Scholar
• Donazzan L, Mahfoud F, Ewen S, et al. Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clin Res Cardiol. 2016;105(4):364–371.
   PubMed Web of Science ®Google Scholar
• Hering D, Marusic P, Walton AS, et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension. 2014;64(1):118–124.
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–1281.
   PubMed Web of Science ®Google Scholar
• Symplicity HTNI. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–917.
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–629.
   PubMed Web of Science ®Google Scholar
• Symplicity HTNI, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–1909.
   PubMed Web of Science ®Google Scholar
• Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976–2982.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–1401.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–227.
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Schmieder RE, Azizi M, et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J. 2017;38(44):3272–3281.
   PubMed Web of Science ®Google Scholar
• Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–1965.
   PubMed Web of Science ®Google Scholar
• Azizi M, Pereira H, Hamdidouche I, et al. Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. Circulation. 2016;134(12):847–857.
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Ziakas A, Dimitriadis K, et al. Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry. Clin Res Cardiol. 2017;106(5):322–330.
   PubMed Web of Science ®Google Scholar
• Sata Y, Head GA, Denton K, et al. Role of the Sympathetic Nervous System and Its Modulation in Renal Hypertension. Front Med (Lausanne). 2018 Mar 29;5: 82.
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Mancia G, Schmieder R, et al. Renal Denervation in High-Risk Patients With Hypertension. J Am Coll Cardiol. 2020;75(23):2879–2888.
   PubMed Web of Science ®Google Scholar
• Brinker S, Pandey A, Ayers C, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63(8):834–835.
   PubMed Web of Science ®Google Scholar
• Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–774.
   PubMed Web of Science ®Google Scholar
• Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855–861.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Bohm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–2355.
   PubMed Web of Science ®Google Scholar
• Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30(2):83–89.
   PubMed Web of Science ®Google Scholar
• Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–2170.
   PubMed Web of Science ®Google Scholar
• Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–2345.
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Kiuchi MG, Esler MD. Renal Denervation-Ready for Prime Time!? The Steep SPYRAL Stairs to RADIANCE in Hypertension Treatment. Hypertension. 2018;72(2):287–290.
   PubMed Web of Science ®Google Scholar
• Bohm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451.
   PubMed Web of Science ®Google Scholar
• Azizi M, Daemen J, Lobo MD, et al. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC Cardiovasc Interv. 2020;13(24):2922–2933.
   PubMed Web of Science ®Google Scholar
• Bohm M, Mahfoud F, Ukena C, et al. Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry. EuroIntervention. 2013;9(4):484–492.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;63(25Pt B):2889–2934. 2014.
   PubMedGoogle Scholar
• Maqsood MH, Rubab K, Anwar F, et al. A Systematic Review of Randomized Controlled Trials Comparing Renal Sympathetic Denervation versus Sham Procedure for the Management of Uncontrolled Hypertension. J Cardiovasc Pharmacol. 2021;77(2):153–158.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2032–2043.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338(may19 1):b1665.
   PubMedGoogle Scholar
• Kario K, Kim BK, Aoki J, et al. Renal Denervation in Asia: consensus Statement of the Asia Renal Denervation Consortium. Hypertension. 2020;75(3):590–602.
   PubMed Web of Science ®Google Scholar
• Ewen S, Ukena C, Linz D, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension. 2015;65(1):193–199.
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Bakris G, Bhatt DL, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J. 2017;38(2):93–100.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. 2018.
   PubMed Web of Science ®Google Scholar
• Lobo MD, Sharp ASP, Kapil V, et al. Joint UK societies’ 2019 consensus statement on renal denervation. Heart. 2019;105(19):1456–1463.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Hogerl K, Jung S, et al. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;8(12):1331–1342.
   Google Scholar
• Schmieder RE, Mahfoud F, Azizi M, et al. European Society of Hypertension position paper on renal denervation. J Hypertens. 2018;36(10):2042–2048. 2018.
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Schlaich MP, Lobo MD. Device Therapy of Hypertension. Circ Res. 2021;128(7):1080–1099.
   PubMed Web of Science ®Google Scholar
• Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–909.
   PubMed Web of Science ®Google Scholar
• Kiuchi MG, Mion D. Chronic kidney disease and risk factors responsible for sudden cardiac death: a whiff of hope? Kidney Res Clin Pract. 2016;35(1):3–9.
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Urban D, Teller D, et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J. 2014;35(33):2224–31b.
   PubMed Web of Science ®Google Scholar
• Kiuchi MG, Chen SJ, Andrea BR, et al. Renal Sympathetic Denervation in Patients With Hypertension and Chronic Kidney Disease: does Improvement in Renal Function Follow Blood Pressure Control? J Clin Hypertens. 2014;16(11):794–800.
   Web of Science ®Google Scholar
• Delacroix S, Chokka RG, Sahay S, et al. Renal sympathetic denervation increases renal blood volume per cardiac cycle: a serial magnetic resonance imaging study in resistant hypertension. Int J Nephrol Renovasc Dis. 2017;10:243-249.
   Google Scholar
• Kiuchi MG, Maia GLM, Carreira MAMD, et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J. 2013;34(28):2114–2121.
   PubMed Web of Science ®Google Scholar
• Ott C, Mahfoud F, Schmid A, et al. Improvement of albuminuria after renal denervation. Int J Cardiol. 2014 May 1;173(2):311–315.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Mahfoud F, Schmid A, et al. Improvement of Albuminuria after Renal Denervation. J Am Coll Cardiol. 2014;63(12):A2055–A.
   Web of Science ®Google Scholar
• Ukena C, Bauer A, Mahfoud F, et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol. 2012;101(1):63–67.
   PubMed Web of Science ®Google Scholar
• Ukena C, Mahfoud F, Ewen S, et al. Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. Clin Res Cardiol. 2016;105(10):873–879.
   PubMed Web of Science ®Google Scholar
• Mark DB, Anstrom KJ, Sheng S, et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: the CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1275–1285.
   PubMed Web of Science ®Google Scholar
• Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):157–208.
   PubMed Web of Science ®Google Scholar
• Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: the CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261–1274.
   PubMed Web of Science ®Google Scholar
• Remo BF, Preminger M, Bradfield J, et al. Safety and efficacy of renal denervation as a novel treatment of ventricular tachycardia storm in patients with cardiomyopathy. Heart Rhythm. 2014;11(4):541–546.
   PubMed Web of Science ®Google Scholar
• Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13):1163–1170.
   PubMed Web of Science ®Google Scholar
• Steinberg JS, Shabanov V, Ponomarev D, et al. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: the ERADICATE-AF Randomized Clinical Trial. JAMA. 2020;323(3):248–255.
   PubMed Web of Science ®Google Scholar
• Bohm M, Ewen S, Kindermann I, et al. Renal denervation and heart failure. Eur J Heart Fail. 2014;16(6):608–613.
   PubMed Web of Science ®Google Scholar
• Warchol-Celinska E, Prejbisz A, Kadziela J, et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: randomized Proof-of-Concept Phase II Trial. Hypertension. 2018;72(2):381–390.
   PubMed Web of Science ®Google Scholar